Checchi Capital Advisers LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 4.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 33,545 shares of the company’s stock after selling 1,409 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Johnson & Johnson were worth $5,199,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of the stock. Moneta Group Investment Advisors LLC increased its position in shares of Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Johnson & Johnson by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock valued at $8,456,643,000 after purchasing an additional 294,671 shares during the last quarter. Morgan Stanley increased its position in shares of Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after purchasing an additional 3,849,148 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $4,609,399,000. Institutional investors own 67.57% of the company’s stock.
Johnson & Johnson Trading Up 1.0 %
JNJ opened at $173.85 on Monday. The firm has a market cap of $451.83 billion, a price-to-earnings ratio of 35.19, a PEG ratio of 2.92 and a beta of 0.54. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04. The stock has a fifty day moving average price of $164.90 and a 200-day moving average price of $161.14.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 2.74%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 96.36%.
Analysts Set New Price Targets
A number of research firms recently issued reports on JNJ. Stifel Nicolaus boosted their price objective on Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Morgan Stanley restated an “equal weight” rating and set a $187.00 price objective on shares of Johnson & Johnson in a report on Friday, July 21st. Barclays boosted their price objective on Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a report on Monday, July 24th. Finally, Credit Suisse Group upped their target price on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Eight analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $171.80.
Get Our Latest Analysis on JNJ
Insider Activity at Johnson & Johnson
In related news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The disclosure for this sale can be found here. Insiders have sold 47,163 shares of company stock valued at $7,928,856 in the last ninety days. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- With Risk Tolerance, One Size Does Not Fit All
- MarketBeat Week in Review – 8/7 – 8/11
- How Investors Can Identify and Successfully Trade Gap-Up Stocks
- 3 Retailers To Watch Closely Next Week
- How to Start Investing in Penny Stocks
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
